LIFECORE BIOMEDICAL, INC. Deferred Tax Asset, Interest Carryforward
LIFECORE BIOMEDICAL, INC. (LFCR) had Deferred Tax Asset, Interest Carryforward of $17.83 million as of 2025-12-31, per its 10-KT filed 2026-03-16.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetInterestCarryforward · last filed 2026-03-16
- 2025-12-31: Deferred Tax Asset, Interest Carryforward $17.83M.
- 2025-05-25: Deferred Tax Asset, Interest Carryforward $15.57M.
- 2024-05-26: Deferred Tax Asset, Interest Carryforward $11.78M.
- 2023-05-28: Deferred Tax Asset, Interest Carryforward $8.61M.
| Period end | Deferred Tax Asset, Interest Carryforward | Deferred Tax Asset, Interest Carryforward as first filed |
|---|---|---|
| 2025-12-31 | $17.83M 10-KT · filed 2026-03-16 | |
| 2025-05-25 | $15.57M 10-KT · filed 2026-03-16 | |
| 2024-05-26 | $11.78M 10-KT · filed 2026-03-16 | |
| 2023-05-28 | $8.61M 10-K · filed 2024-08-26 | |
| 2022-05-29 | $3.50M 10-K · filed 2024-03-20 | $4.25M 10-K · filed 2022-09-14 |
| 2021-05-30 | $2.11M 10-K · filed 2024-03-20 | $2.41M 10-K · filed 2021-07-29 |
| 2020-05-31 | $2.08M 10-K · filed 2021-07-29 | |
| 2019-05-26 | $0.00 10-K · filed 2020-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |